IDEMIA Announces a Global Partnership With Bosch Building Technologies to Tap the $1bn Biometric Access Control Market
13.7.2021 13:46:00 EEST | Business Wire | Press release
IDEMIA, the leader of Augmented Identity announced today a global partnership with Bosch Building Technologies, a global leader in the security market, to tap the fast-growing biometric access control market. According to market analysts1, this market at $1bn in 2021, will grow to $1.4 by 2024, twice the growth of traditional access control systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005582/en/
(Photo: Business Wire)
This booming market comes from the fact that a growing number of companies understand that for their security, they cannot rely anymore only on simple ID badges, that can be cloned (for older technologies still used by 44% of companies2) or simply stolen. The consequence is that it is never possible to know with certainty who is entering the premises. Biometrics, based on personal, physiological, unforgeable characteristics, provide the highest degree of certainty that the person passing the door is a genuine authorized employee. Bosch Building Technologies offers a software solution that manages different Bosch security subsystems like access control, video surveillance, fire alarm, public address and intrusion systems on one single platform, the Bosch Building Integration System (BIS). This robust and reliable security and life safety system is proven by over 3000 installations integrating 10 million detectors worldwide.
In order to add a biometric layer to BIS, Bosch has selected IDEMIA’s terminals: IDEMIA is the market leader of biometrics for access control with more than 25 year’s experience in that domain, and hundreds of thousands of terminals successfully deployed for a great variety of industries, throughout the world.
Bosch will offer IDEMIA’s flagship contactless biometric terminals:
- MorphoWaveTM , the only terminal in the world capable of scanning and verifying 4 fingerprints in less than 1 second through a quick, simple and fully touchless wave movement of the hand,
- VisionPass the most advanced facial recognition terminal combining 2D, 3D and infrared cameras with IDEMIA’s leading facial algorithms.
Both terminals combine high biometric accuracy, speed and convenience with a fully touchless user experience. They operate efficiently with sanitary masks and are therefore well adapted for Covid-prevention policies. IDEMIA terminals are already integrated with the BIS platform and with most gates and turnstile vendors. This will greatly facilitate deployments in Bosch specific markets with a focus on commercial buildings, industrial and logistics sites, government premises and airports/seaports.
“Bosch stands for quality and reliability. We want to offer innovative and fascinating solutions, as our slogan 'invented for life' states. When our customers are going to deploy biometric terminals for their security, they will be installed for years so we want to offer them the best option”, explains Gregor Schlechtriem, Senior Vice President Bosch Building Technologies Business Unit Access & Intrusion. “Idemia is therefore for us the right partner because of their technology expertise and field-proven quality and performances”, Schlechtriem continues.
“We are delighted to start this global partnership with Bosch”, commented Yves Portalier, EVP Biometric Devices and Automotive at IDEMIA. “The combination of our biometric devices with the BIS platform will be a strong offering for companies looking for a high level of security and user convenience”.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
1 In particular leading market analysis firm OMDIA
2 According to a ASIS International 2019 survey
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005582/en/
Contact information
Press contact
IDEMIA:
Hanna SEBBAH
idemia@havas.com
+33 (0) 6 63 73 30 30
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
